Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
07 July 2023 | Story André Damons | Photo Supplied
Dr Osayande Evbuomwan
Dr Osayande Evbuomwan, Senior Lecturer and Medical Specialist in the Department of Nuclear Medicine at the University of the Free State (UFS), with his certificate after winning the Society of Nuclear Medicine and Molecular Imaging (SNMMI) International Best Abstract Award for South Africa.

A research paper by a Senior Lecturer and Medical Specialist in the Department of Nuclear Medicine at the University of the Free State (UFS) has won the Society of Nuclear Medicine and Molecular Imaging (SNMMI) International Best Abstract Award for South Africa.

The abstract, by Dr Osayande Evbuomwan, was about evaluating the efficacy of a new nuclear medicine radiopharmaceutical in the identification of active disease in patients with rheumatoid arthritis. It was selected for this award by a special committee at the recently concluded SNMMI 2023 Annual Meeting, which took place between 24 and 27 June in Chicago, USA.

Dr Evbuomwan received the award at the Annual Meeting on 26 June.

“It is a good feeling, and I am proud of the UFS Department of Nuclear Medicine for pulling this off. It is another example that hard work pays,” he says.

Comparing this radiopharmaceutical to ultrasound

Dr Evbuomwan says the research that generated the award-winning abstract was aimed at finding out if the new nuclear medicine radiopharmaceutical for the identification of active disease in patients with rheumatoid arthritis can also offer prognostic information. The study concluded that this particular radiopharmaceutical (Tc – 99m glucosamine) is highly sensitive in identifying synovitis (inflammation of the membrane that protects joints), and is capable of offering prognostic information in patients with rheumatoid arthritis.

This is the first prospective study to assess the prognostic value of this radiopharmaceutical in patients with rheumatoid arthritis, Dr Evbuomwan says. He is currently working on comparisons of this radiopharmaceutical to ultrasound and clinical evaluation in the identification of active disease in patients with rheumatoid arthritis. He says there is also ongoing collaboration with the Rheumatology Division of the Internal Medicine Department, which has played a huge role in making this project fruitful.

“This award is an opportunity to put the department and university on the map, with world stage recognition. We believe that as the Nuclear Medicine Department continues to grow in human resources and equipment, the research output will also increase.”

Dr Gerrit Engelbrecht, Clinical Head of the Department of Nuclear Medicine at the UFS, says the whole department is very proud of Dr Evbuomwan’s accomplishments. “What makes his award even more remarkable is that he outperformed candidates from much larger, highly funded institutions,” he says.

This department announced last year the successful treatment outcome of a patient with metastatic castrate-resistant prostate cancer (MCRPC) – an advanced stage of prostate cancer – by using Lutetium 177 PSMA (Lu-177 PSMA) therapy. This was initially a case of advanced stage prostate cancer, which had failed first-line chemotherapy, leaving little or no other treatment options.

News Archive

UFS council approves guidelines for reconfiguration of Vista Campus
2005-03-15

Human resource development (teaching and training) will be the primary aim of services to be rendered at the reconfigured Vista campus of the University of the Free State (UFS).

This in-principle decision forms part of a set of guidelines for the strategic reconfiguration of the Vista campus in Bloemfontein that was recently approved by the UFS Council.  The Vista campus was incorporated into the UFS in January 2004.

“One of the most important aspects that resulted from these guidelines is that we have come to a point where I can say that the future of staff at Vista is not dependant on the strategic reconfiguration of the campus.  Vista staff members will stay staff of the UFS and are being integrated into the functions of the main campus,” said Prof Magda Fourie, Vice-Rector:  Academic Planning at the UFS.

“According to the guidelines, the reconfiguration of the Vista campus must occur within the ambit of the UFS as a single institution with three campuses,” said Prof Fourie.

The UFS is currently offering two activities on the Vista campus – the regional Centre for Recognition of Prior Learning (RPL) and the Sesotho Language Research and Development Centre. 

According to Prof Fourie no duplication of services or programmes being rendered on the main campus in Bloemfontein will take place.  In the guidelines suggestions are made that the Vista campus could be used for activities that are currently offered on the main campus (eg short learning programmes), new UFS activities (mainly of a developmental and entrepreneurial nature), cooperative partnership ventures with other role-players and the renting of facilities for education and training purposes. 

“However, no definite decisions have been made about these possible activities – the necessary consultation process with relevant stakeholders and role-players must first take place.  A consultative forum for this will be established early in the second term of this year,” said Prof Fourie.

 “We are excited about the possibilities that have arised from the guidelines as it fits in with our vision to utilise new resources for education and training and to contribute to higher education in the Free State.  This will also contribute to the development of human resources as a propelling force in the Central Region,” said Prof Fourie.
 

MEDIA RELEASE
Issued by: Lacea Loader
Media Representative
Tel:  (051) 401-2584
Cell:  083 645 2454
E-mail:  loaderl.stg@mail.uovs.ac.za
15 March 2005

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept